HUE035985T2 - HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma - Google Patents

HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma

Info

Publication number
HUE035985T2
HUE035985T2 HUE10181268A HUE10181268A HUE035985T2 HU E035985 T2 HUE035985 T2 HU E035985T2 HU E10181268 A HUE10181268 A HU E10181268A HU E10181268 A HUE10181268 A HU E10181268A HU E035985 T2 HUE035985 T2 HU E035985T2
Authority
HU
Hungary
Prior art keywords
dosage form
hiv protease
pharmaceutical dosage
protease inhibitor
solid
Prior art date
Application number
HUE10181268A
Other languages
English (en)
Inventor
Joerg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Berndl
Laman Alani
Soumojeet Ghosh
Joerg Breitenbach
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE035985(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HUE035985T2 publication Critical patent/HUE035985T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HUE10181268A 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma HUE035985T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/650,178 US20050048112A1 (en) 2003-08-28 2003-08-28 Solid pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
HUE035985T2 true HUE035985T2 (hu) 2018-06-28

Family

ID=34217089

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE10181268A HUE035985T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma
HUE10181264A HUE031153T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma
HUE15169378A HUE038792T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE10181264A HUE031153T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma
HUE15169378A HUE038792T2 (hu) 2003-08-28 2004-08-23 HIV proteáz inhibitor szilárd diszperziót tartalmazó szilárd gyógyászati dózisforma

Country Status (31)

Country Link
US (1) US20050048112A1 (hu)
EP (6) EP2258346B1 (hu)
JP (6) JP4815348B2 (hu)
KR (5) KR101281994B1 (hu)
CN (5) CN105106104A (hu)
AT (1) ATE516017T1 (hu)
AU (3) AU2004283087C1 (hu)
CA (2) CA2689639C (hu)
CR (3) CR8256A (hu)
CY (5) CY1111981T1 (hu)
DK (5) DK2942051T3 (hu)
EA (4) EA201890737A3 (hu)
EC (1) ECSP066397A (hu)
ES (5) ES2399810T3 (hu)
HK (4) HK1094766A1 (hu)
HR (1) HRP20110555T1 (hu)
HU (3) HUE035985T2 (hu)
IL (3) IL173939A (hu)
ME (2) MEP17608A (hu)
MX (2) MX358033B (hu)
NO (3) NO330282B1 (hu)
NZ (2) NZ579622A (hu)
PL (5) PL1663183T3 (hu)
PT (5) PT2258345T (hu)
RS (2) RS57663B1 (hu)
SG (3) SG179401A1 (hu)
SI (5) SI1663183T1 (hu)
TW (1) TWI342221B (hu)
UA (1) UA85564C2 (hu)
WO (1) WO2005039551A2 (hu)
ZA (3) ZA200801362B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
DK1962808T3 (da) * 2005-12-14 2010-11-08 Hoffmann La Roche HCV prodrug-formulering
SI2051703T1 (sl) * 2005-12-14 2011-01-31 Cipla Ltd Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
EP3150586B1 (en) 2007-02-23 2020-01-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
CN101959506A (zh) * 2008-02-28 2011-01-26 雅培制药有限公司 片剂和其制备方法
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2683378A4 (en) * 2011-03-07 2014-09-03 Hetero Research Foundation AMORPHOUS FORM OF A MIXTURE OF LOPINAVIR AND RITONAVIR
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
JP2014521745A (ja) * 2011-08-16 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用
EP2564832A1 (en) 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2013131645A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
HUE027830T2 (hu) 2012-03-07 2016-11-28 Ratiopharm Gmbh Lopinavirt és ritonavirt tartalmazó dózisforma
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
WO2014048783A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
JP6275726B2 (ja) 2012-09-27 2018-02-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
RU2505286C1 (ru) 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
US20190038754A1 (en) * 2017-08-07 2019-02-07 SE Tylose, USA, Inc. Pharmaceutical composition in solid extruded form
EP3758683A1 (en) * 2018-03-02 2021-01-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
CN113318076B (zh) * 2021-06-02 2022-09-23 聊城大学 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法
CN114557967B (zh) * 2022-03-17 2023-06-02 乐普制药科技有限公司 一种利托那韦固体分散体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5542206A (en) 1994-10-11 1996-08-06 Lisch; Albert Lure and tackle stacking container
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19841244A1 (de) * 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
CA2371109C (en) 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
WO2001034118A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Solid dispersion pharmaceutical formulations
JP2005500313A (ja) 2001-06-22 2005-01-06 ファイザー・プロダクツ・インク 基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP2112925A4 (en) 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS

Also Published As

Publication number Publication date
CY1111981T1 (el) 2015-11-04
UA85564C2 (ru) 2009-02-10
PT1663183E (pt) 2011-08-25
KR20140046078A (ko) 2014-04-17
KR20120054666A (ko) 2012-05-30
PL2258346T3 (pl) 2018-01-31
SG179401A1 (en) 2012-04-27
JP2007504142A (ja) 2007-03-01
IL173939A0 (en) 2006-07-05
DK2258344T3 (da) 2013-01-02
EP2258344A2 (en) 2010-12-08
AU2004283087C1 (en) 2008-04-24
NO20100367L (no) 2006-05-29
HUE031153T2 (hu) 2017-07-28
EP1663183A2 (en) 2006-06-07
EP2258346B1 (en) 2017-09-27
EP2942051B1 (en) 2018-01-17
ES2653762T3 (es) 2018-02-08
AU2004283087B2 (en) 2007-09-20
ECSP066397A (es) 2006-08-30
SI2258346T1 (sl) 2017-12-29
DK2942051T3 (en) 2018-05-07
JP5903413B2 (ja) 2016-04-13
EP3354261A1 (en) 2018-08-01
NO334418B1 (no) 2014-03-03
EP2942051A1 (en) 2015-11-11
EA201890737A3 (ru) 2019-01-31
ZA200601718B (en) 2009-11-25
PT2942051T (pt) 2018-04-23
HK1217298A1 (zh) 2017-01-06
CY1113596T1 (el) 2016-06-22
WO2005039551A3 (en) 2006-08-03
CN105106104A (zh) 2015-12-02
IL207260A (en) 2017-10-31
CN1901884A (zh) 2007-01-24
SG145690A1 (en) 2008-09-29
EP2258345A2 (en) 2010-12-08
AU2004283087A1 (en) 2005-05-06
ES2399810T3 (es) 2013-04-03
EP2258346A2 (en) 2010-12-08
EA201890737A2 (ru) 2018-08-31
MX358033B (es) 2018-08-02
CR20120661A (es) 2013-03-13
SI2258345T1 (sl) 2017-01-31
ES2608720T3 (es) 2017-04-12
KR20150044031A (ko) 2015-04-23
AU2007249115A1 (en) 2008-01-10
CN1901884B (zh) 2012-07-25
DK2258346T3 (da) 2017-11-13
CN102772380B (zh) 2015-08-19
SG10201507902UA (en) 2015-10-29
JP5395125B2 (ja) 2014-01-22
MEP17608A (en) 2010-06-10
ZA200801362B (en) 2009-03-25
AU2007249115B2 (en) 2010-08-12
RS20060140A (en) 2008-09-29
NO20061342L (no) 2006-05-29
EP2258346A3 (en) 2011-01-19
HK1257502A1 (zh) 2019-10-25
CR20120662A (es) 2013-03-13
MXPA06002346A (es) 2006-05-19
ATE516017T1 (de) 2011-07-15
DK1663183T3 (da) 2011-08-29
AU2010238573B2 (en) 2012-12-13
SI2258344T1 (sl) 2013-03-29
EA201301045A1 (ru) 2014-05-30
RS59969B1 (sr) 2020-03-31
PL2258345T3 (pl) 2017-03-31
TWI342221B (en) 2011-05-21
CN102772380A (zh) 2012-11-14
CY1119651T1 (el) 2018-04-04
CN101919858A (zh) 2010-12-22
PL2258344T3 (pl) 2013-04-30
JP2016094433A (ja) 2016-05-26
ME00130B (me) 2010-10-10
HK1094766A1 (en) 2007-04-13
HUE038792T2 (hu) 2018-11-28
CR8256A (es) 2008-01-11
NO330282B1 (no) 2011-03-21
NZ579622A (en) 2011-01-28
JP5498411B2 (ja) 2014-05-21
EP1663183B9 (en) 2012-06-13
CY1120138T1 (el) 2018-12-12
JP2011126898A (ja) 2011-06-30
WO2005039551A2 (en) 2005-05-06
NO335326B1 (no) 2014-11-10
EP2258344A3 (en) 2011-01-19
CA2536638C (en) 2010-04-06
EP1663183B1 (en) 2011-07-13
IL254581A0 (en) 2017-11-30
RS57663B1 (sr) 2018-11-30
EA200600473A1 (ru) 2006-10-27
JP4815348B2 (ja) 2011-11-16
SI1663183T1 (sl) 2011-09-30
TW200522979A (en) 2005-07-16
KR20060121837A (ko) 2006-11-29
JP2013241460A (ja) 2013-12-05
PT2258344E (pt) 2013-02-18
SI2942051T1 (en) 2018-06-29
CA2689639A1 (en) 2005-05-06
HK1145969A1 (en) 2011-05-13
RS20181262A1 (sr) 2019-02-28
EP2258345B1 (en) 2016-09-21
IL173939A (en) 2017-03-30
EA011924B1 (ru) 2009-06-30
EA200900292A1 (ru) 2009-06-30
PL1663183T3 (pl) 2011-10-31
CY1118505T1 (el) 2017-07-12
CA2689639C (en) 2014-06-10
CN102764244A (zh) 2012-11-07
ES2367173T3 (es) 2011-10-31
KR101457967B1 (ko) 2014-11-07
CA2536638A1 (en) 2005-05-06
KR20110122771A (ko) 2011-11-10
EP2258345A3 (en) 2011-01-19
JP2018035163A (ja) 2018-03-08
ZA200801361B (en) 2011-11-30
NO20131743L (no) 2006-05-29
DK2258345T3 (en) 2017-01-16
PT2258345T (pt) 2017-01-20
KR101563222B1 (ko) 2015-10-26
PT2258346T (pt) 2017-10-24
KR101132602B1 (ko) 2012-04-06
HRP20110555T1 (hr) 2011-09-30
US20050048112A1 (en) 2005-03-03
AU2010238573A1 (en) 2010-11-18
JP2011236232A (ja) 2011-11-24
CN101919858B (zh) 2013-10-30
EA033224B1 (ru) 2019-09-30
EP2258344B1 (en) 2012-11-14
EA020992B1 (ru) 2015-03-31
NZ545499A (en) 2009-11-27
ES2666390T3 (es) 2018-05-04
KR101281994B1 (ko) 2013-07-04
PL2942051T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
HK1257502A1 (zh) 一種包含hiv蛋白酶抑制劑固體分散體的固體藥物劑型